Summary:
- This article discusses a large-scale study that examined the cardiovascular benefits of two common diabetes medications, empagliflozin and liraglutide.
- The study, which involved over 1 million patients, found that these drugs can significantly reduce the risk of heart disease, heart failure, and other cardiovascular complications in people with type 2 diabetes.
- The findings are important because they provide strong evidence that these diabetes medications can have a positive impact on heart health, in addition to their primary role in managing blood sugar levels.